Details of the Drug

General Information of Drug (ID: DMNO38U)

• Drug Name: Bortezomib
• Synonyms: 179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate

Indication

Disease Entry	ICD 11	Status	REF
Leukemia	N.A.	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Lymphoproliferative syndrome	N.A.	Approved	[1]
MALT lymphoma	N.A.	Approved	[1]
Mantle cell lymphoma	2A85.5	Approved	[2]
Minimally invasive lung adenocarcinoma	N.A.	Approved	[1]
Multiple myeloma	2A83	Approved	[3]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[1]
Non-hodgkin lymphoma	2B33.5	Phase 3	[3]
B-cell neoplasm	N.A.	Investigative	[1]
Colon cancer	2B90.Z	Investigative	[1]
Gastric cancer	2B72	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 384.2
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 9
  Hydrogen Bond Donor Count; 4
  Hydrogen Bond Acceptor Count; 6
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 57 mcg/L [4]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
  Clearance: The total body clearance of drug is 102-112 L/h [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 40 - 193 hours [4]
  Metabolism: The drug is metabolized via the CYP3A4, CYP2C19, and CYP1A2 [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0836 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.17% [7]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 10 L/kg [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 3.3 mg/mL [5]
• Chemical Identifiers:
  Formula: C19H25BN4O4
  IUPAC Name: [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
  Canonical SMILES: B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
  InChI: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
  InChIKey: GXJABQQUPOEUTA-RDJZCZTQSA-N
• Cross-matching ID:
  PubChem CID: 387447
  ChEBI ID: CHEBI:52717
  CAS Number: 179324-69-7
  DrugBank ID: DB00188
  TTD ID: D0SH3I
  VARIDT ID: DR01331
  INTEDE ID: DR0221
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Inhibitor	[8]
Kallikrein-related peptidase (KLK)	TT5L2VC	NOUNIPROTAC	Inhibitor	[8]
Proteasome (PS)	TTU7ZMG	NOUNIPROTAC	Modulator	[9]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[14]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
14-3-3 protein epsilon	OT3WQXNA	1433E_HUMAN	Gene/Protein Processing	[15]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[15]
14-3-3 protein zeta/delta	OT2TKG9P	1433Z_HUMAN	Gene/Protein Processing	[15]
2-oxoglutarate dehydrogenase complex component E1 (OGDH)	OTHGTQWF	ODO1_HUMAN	Gene/Protein Processing	[15]
26S proteasome non-ATPase regulatory subunit 12 (PSMD12)	OTWICA51	PSD12_HUMAN	Gene/Protein Processing	[15]
26S proteasome non-ATPase regulatory subunit 13 (PSMD13)	OTNQ351N	PSD13_HUMAN	Gene/Protein Processing	[15]
26S proteasome non-ATPase regulatory subunit 7 (PSMD7)	OT7PZZ4K	PSMD7_HUMAN	Gene/Protein Processing	[15]
26S proteasome regulatory subunit 6B (PSMC4)	OTS3XN41	PRS6B_HUMAN	Gene/Protein Processing	[15]
5'-nucleotidase (NT5E)	OT7J5LT6	5NTD_HUMAN	Gene/Protein Processing	[15]
5-hydroxytryptamine receptor 2B (HTR2B)	OTM1AD9J	5HT2B_HUMAN	Gene/Protein Processing	[15]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bortezomib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Carfilzomib	DM48K0X	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Carfilzomib.	Multiple myeloma [2A83]	[16]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Thalidomide.	Multiple myeloma [2A83]	[16]
Elotuzumab	DMEYHG9	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Elotuzumab.	Multiple myeloma [2A83]	[16]

Coadministration of a Drug Treating the Disease Different from Bortezomib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[17]
Metreleptin	DM1NOEK	Minor	Increased metabolism of Bortezomib caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[18]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Thioguanine.	Acute myeloid leukaemia [2A60]	[19]
Ivosidenib	DM8S6T7	Minor	Increased metabolism of Bortezomib caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[18]
Arn-509	DMT81LZ	Major	Increased metabolism of Bortezomib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[18]
Mitotane	DMU1GX0	Major	Increased metabolism of Bortezomib caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[18]
Metronidazole	DMTIVEN	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Metronidazole.	Amoebiasis [1A36]	[16]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[20]
Butalbital	DM9J04X	Minor	Increased metabolism of Bortezomib caused by Butalbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[18]
Methylphenobarbital	DMDSWAG	Minor	Increased metabolism of Bortezomib caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[18]
Clobazam - Lundbeck	DMW1OQ0	Minor	Decreased metabolism of Bortezomib caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[21]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Bortezomib caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[22]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Bortezomib caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[23]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Bortezomib caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[23]
Zafirlukast	DMHNQOG	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Zafirlukast.	Asthma [CA23]	[16]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Bortezomib and Roflumilast.	Asthma [CA23]	[18]
Oritavancin	DM28D05	Minor	Increased metabolism of Bortezomib caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Tindamax	DM3OWT4	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Tindamax.	Bacterial infection [1A00-1C4Z]	[16]
Erythromycin	DM4K7GQ	Moderate	Decreased metabolism of Bortezomib caused by Erythromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Bortezomib caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Chloramphenicol	DMFXEWT	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Chloramphenicol.	Bacterial infection [1A00-1C4Z]	[16]
Linezolid	DMGFPU2	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Linezolid.	Bacterial infection [1A00-1C4Z]	[16]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Bortezomib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Bortezomib caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bortezomib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[24]
Eribulin	DM1DX4Q	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Eribulin.	Breast cancer [2C60-2C6Y]	[16]
Ixabepilone	DM2OZ3G	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Ixabepilone.	Breast cancer [2C60-2C6Y]	[16]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Bortezomib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Bortezomib caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Cabazitaxel	DMPAZHC	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Cabazitaxel.	Breast cancer [2C60-2C6Y]	[16]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[16]
Atorvastatin	DMF28YC	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Atorvastatin.	Cardiovascular disease [BA00-BE2Z]	[16]
Secobarbital	DM14RF5	Minor	Increased metabolism of Bortezomib caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[18]
Phenylbutazone	DMAYL0T	Minor	Increased metabolism of Bortezomib caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[18]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Oxaliplatin.	Colorectal cancer [2B91]	[16]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Bortezomib caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[17]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Bortezomib caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Bortezomib caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[23]
Griseofulvin	DMK54YG	Minor	Increased metabolism of Bortezomib caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[18]
PMID28454500-Compound-96	DM2A75P	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and PMID28454500-Compound-96.	Discovery agent [N.A.]	[16]
Citalopram derivative 1	DMITX1G	Minor	Decreased metabolism of Bortezomib caused by Citalopram derivative 1 mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[21]
Diazepam	DM08E9O	Minor	Decreased metabolism of Bortezomib caused by Diazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Primidone	DM0WX6I	Major	Increased metabolism of Bortezomib caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Felbamate	DM1V5ZS	Minor	Increased metabolism of Bortezomib caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Oxcarbazepine	DM5PU6O	Minor	Increased metabolism of Bortezomib caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Mephenytoin	DM5UGDK	Minor	Decreased metabolism of Bortezomib caused by Mephenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Valproate	DMCFE9I	Minor	Decreased metabolism of Bortezomib caused by Valproate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Cenobamate	DM8KLU9	Minor	Increased metabolism of Bortezomib caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Bortezomib caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Bortezomib caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Rufinamide	DMWE60C	Minor	Increased metabolism of Bortezomib caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Bortezomib caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Bortezomib caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Eslicarbazepine	DMZREFQ	Minor	Increased metabolism of Bortezomib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Tazemetostat	DMWP1BH	Minor	Increased metabolism of Bortezomib caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[18]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Bortezomib caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Terbinafine	DMI6HUW	Minor	Decreased metabolism of Bortezomib caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[21]
Clotrimazole	DMMFCIH	Moderate	Decreased metabolism of Bortezomib caused by Clotrimazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Bortezomib caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Omeprazole	DM471KJ	Minor	Decreased metabolism of Bortezomib caused by Omeprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[21]
Pantoprazole	DMSVOCZ	Minor	Decreased metabolism of Bortezomib caused by Pantoprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[21]
Colchicine	DM2POTE	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Colchicine.	Gout [FA25]	[16]
Sulfinpyrazone	DMEV954	Minor	Increased metabolism of Bortezomib caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[18]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Bortezomib caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[23]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Bortezomib caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[23]
Telbivudine	DMSWUGE	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Telbivudine.	Hepatitis virus infection [1E50-1E51]	[16]
Isoniazid	DM5JVS3	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Rifampin	DMA8J1G	Major	Increased metabolism of Bortezomib caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Rifapentine	DMCHV4I	Major	Increased metabolism of Bortezomib caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[18]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[28]
Indinavir	DM0T3YH	Moderate	Decreased metabolism of Bortezomib caused by Indinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Bortezomib caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Bortezomib caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Stavudine	DM6DEK9	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Stavudine.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Nevirapine	DM6HX9B	Minor	Increased metabolism of Bortezomib caused by Nevirapine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Bortezomib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Efavirenz	DMC0GSJ	Minor	Increased metabolism of Bortezomib caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Bortezomib caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Etravirine	DMGV8QU	Minor	Increased metabolism of Bortezomib caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Didanosine	DMI2QPE	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Bortezomib caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Bortezomib caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Bortezomib caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Fluvastatin	DM4MDJY	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Fluvastatin.	Hyper-lipoproteinaemia [5C80]	[16]
Lovastatin	DM9OZWQ	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Lovastatin.	Hyper-lipoproteinaemia [5C80]	[16]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Bortezomib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[29]
Rosuvastatin	DMMIQ7G	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Rosuvastatin.	Hyper-lipoproteinaemia [5C80]	[16]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Bortezomib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[30]
Hydralazine	DMU8JGH	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Hydralazine.	Hypertension [BA00-BA04]	[16]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Bortezomib caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[31]
Pirfenidone	DM6VZFQ	Minor	Decreased metabolism of Bortezomib caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[21]
Lesinurad	DMUR64T	Minor	Increased metabolism of Bortezomib caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[18]
Auranofin	DMWE2N4	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Auranofin.	Inflammatory arthropathy [FA2Z]	[16]
Amobarbital	DM0GQ8N	Minor	Increased metabolism of Bortezomib caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Butabarbital	DMC5AST	Minor	Increased metabolism of Bortezomib caused by Butabarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Pentobarbital	DMFNH7L	Minor	Increased metabolism of Bortezomib caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Quazepam	DMY4D87	Minor	Decreased metabolism of Bortezomib caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[21]
Nelarabine	DMB6VEG	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Nelarabine.	Leukaemia [2A60-2B33]	[16]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Bortezomib caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[18]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Bortezomib and Denosumab.	Low bone mass disorder [FB83]	[32]
Brigatinib	DM7W94S	Minor	Increased metabolism of Bortezomib caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[18]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Bortezomib caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Bortezomib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[17]
Osimertinib	DMRJLAT	Minor	Increased metabolism of Bortezomib caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[18]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Bortezomib caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[33]
Chloroquine	DMSI5CB	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Chloroquine.	Malaria [1F40-1F45]	[16]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Hydroxychloroquine.	Malaria [1F40-1F45]	[16]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[34]
Cladribine	DM3JDRP	Major	Additive myelosuppressive effects by the combination of Bortezomib and Cladribine.	Mature B-cell leukaemia [2A82]	[18]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Idelalisib.	Mature B-cell leukaemia [2A82]	[35]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Clofarabine.	Mature B-cell lymphoma [2A85]	[36]
Vincristine	DMINOX3	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Vincristine.	Mature B-cell lymphoma [2A85]	[16]
Teniposide	DMLW57T	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Teniposide.	Mature B-cell lymphoma [2A85]	[16]
Ponatinib	DMYGJQO	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Ponatinib.	Mature B-cell lymphoma [2A85]	[16]
Vemurafenib	DM62UG5	Minor	Increased metabolism of Bortezomib caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Ipilimumab	DMJTIYK	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Ipilimumab.	Melanoma [2C30]	[16]
Dabrafenib	DMX6OE3	Minor	Increased metabolism of Bortezomib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Propranolol	DM79NTF	Minor	Decreased metabolism of Bortezomib caused by Propranolol mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[21]
Exjade	DMHPRWG	Minor	Increased metabolism of Bortezomib caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[18]
Flibanserin	DM70DTN	Minor	Decreased metabolism of Bortezomib caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[21]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Bortezomib and Tecfidera.	Multiple sclerosis [8A40]	[37]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Bortezomib and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Bortezomib and Fingolimod.	Multiple sclerosis [8A40]	[38]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Bortezomib and Ocrelizumab.	Multiple sclerosis [8A40]	[39]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Bortezomib and Ozanimod.	Multiple sclerosis [8A40]	[18]
Carisoprodol	DMWR1JC	Minor	Decreased metabolism of Bortezomib caused by Carisoprodol mediated inhibition of CYP450 enzyme.	Musculoskeletal disorder [FA00-FC0Z]	[21]
Rifabutin	DM1YBHK	Major	Increased metabolism of Bortezomib caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[18]
Bexarotene	DMOBIKY	Minor	Increased metabolism of Bortezomib caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[18]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Bortezomib caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Bortezomib caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[40]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Bortezomib and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[41]
Modafinil	DMYILBE	Minor	Increased metabolism of Bortezomib caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[18]
Carboplatin	DMG281S	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Carboplatin.	Ovarian cancer [2C73]	[16]
Levodopa	DMN3E57	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Levodopa.	Parkinsonism [8A00]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Bortezomib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[42]
Esomeprazole	DM7BN0X	Minor	Decreased metabolism of Bortezomib caused by Esomeprazole mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[21]
Dapsone	DM4LT8A	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Dapsone.	Pneumonia [CA40]	[16]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Bortezomib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[23]
Enzalutamide	DMGL19D	Major	Increased metabolism of Bortezomib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[18]
Bosentan	DMIOGBU	Minor	Increased metabolism of Bortezomib caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[18]
Tocilizumab	DM7J6OR	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Tocilizumab.	Rheumatoid arthritis [FA20]	[16]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Bortezomib and Canakinumab.	Rheumatoid arthritis [FA20]	[43]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Bortezomib and Rilonacept.	Rheumatoid arthritis [FA20]	[43]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Bortezomib and Golimumab.	Rheumatoid arthritis [FA20]	[44]
Dexamethasone	DMMWZET	Minor	Increased metabolism of Bortezomib caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Nafcillin	DMN9RPO	Minor	Increased metabolism of Bortezomib caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Bortezomib and Leflunomide.	Rheumatoid arthritis [FA20]	[45]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Bortezomib when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[46]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Bortezomib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[18]
Vinblastine	DM5TVS3	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Vinblastine.	Solid tumour/cancer [2A00-2F9Z]	[16]
Docetaxel	DMDI269	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[16]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Armodafinil	DMGB035	Minor	Increased metabolism of Bortezomib caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Etoposide	DMNH3PG	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Etoposide.	Solid tumour/cancer [2A00-2F9Z]	[16]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Cisplatin	DMRHGI9	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Taxol	DMUOT9V	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Taxol.	Solid tumour/cancer [2A00-2F9Z]	[16]
Vinorelbine	DMVXFYE	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Vinorelbine.	Solid tumour/cancer [2A00-2F9Z]	[16]
Disulfiram	DMCL2OK	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Disulfiram.	Substance abuse [6C40]	[16]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Bortezomib and Naltrexone.	Substance abuse [6C40]	[47]
Warfarin	DMJYCVW	Minor	Decreased metabolism of Bortezomib caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[21]
Anagrelide	DMSQ8MD	Moderate	Decreased metabolism of Bortezomib caused by Anagrelide mediated inhibition of CYP450 enzyme.	Thrombocytosis [3B63]	[17]
Clopidogrel	DMOL54H	Moderate	Decreased metabolism of Bortezomib caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[48]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Bortezomib and Azathioprine.	Transplant rejection [NE84]	[17]
Ethambutol	DMR87LC	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Ethambutol.	Tuberculosis [1B10-1B12]	[16]
Nitrofurantoin	DM7PQIK	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Nitrofurantoin.	Urinary tract infection [GC08]	[16]
Elagolix	DMB2C0E	Minor	Increased metabolism of Bortezomib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[18]
Secnidazole	DMJ18YL	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Secnidazole.	Vaginal discharge [MF3A]	[16]
Amiodarone	DMUTEX3	Moderate	Increased risk of peripheral neuropathy by the combination of Bortezomib and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[16]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Bortezomib and Valganciclovir.	Virus infection [1A24-1D9Z]	[17]

References

• [1] Bortezomib FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
• [4] FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use
• [5] BDDCS applied to over 900 drugs
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.
• [11] Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
• [12] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [13] Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
• [14] Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7.
• [15] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [16] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
• [17] Cerner Multum, Inc. "Australian Product Information.".
• [18] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [19] Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
• [20] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [21] Product Information. Velcade (bortezomib). Millennium Pharmaceuticals Inc, Cambridge, MA.
• [22] Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
• [23] Pekol T, Daniels JS, Labutti J, et al "Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites." Drug Metab Dispos 33 (2005): 771-7. [PMID: 15764713]
• [24] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [25] Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
• [26] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
• [27] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [28] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [29] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [30] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [31] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [32] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [33] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [34] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [35] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [36] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [37] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [38] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [39] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [40] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [41] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [42] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [43] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [44] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [45] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [46] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [47] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [48] Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]